These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16518335)

  • 1. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy?
    Ng YY; Yang WC; Lee ST
    Kidney Int; 2006 Feb; 69(4):776. PubMed ID: 16518335
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent.
    Tang S; Lai KN
    Kidney Int; 2006 Aug; 70(4):818. PubMed ID: 16900222
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy.
    Chuang TW; Hung CH; Huang SC; Lee CM
    J Formos Med Assoc; 2007 Oct; 106(10):869-73. PubMed ID: 17964968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing clinical development programs for anti-hepatitis B virus drugs.
    Brown NA
    Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
    [No Abstract]   [Full Text] [Related]  

  • 9. Lamivudine and HBV-associated nephropathy.
    Izzedine H; Massard J; Poynard T; Deray G
    Nephrol Dial Transplant; 2006 Mar; 21(3):828-9. PubMed ID: 16263733
    [No Abstract]   [Full Text] [Related]  

  • 10. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.
    Locarnini S
    J Gastroenterol Hepatol; 2010 Apr; 25(4):649-51. PubMed ID: 20492319
    [No Abstract]   [Full Text] [Related]  

  • 11. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine.
    Filler G; Feber J; Weiler G; Le Saux N
    Arch Dis Child; 2003 May; 88(5):460. PubMed ID: 12716731
    [No Abstract]   [Full Text] [Related]  

  • 12. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
    Degertekin B; Lok AS
    J Hepatol; 2008 Jun; 48(6):892-4. PubMed ID: 18433924
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
    Yokosuka O
    J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy.
    Yang Y; Ma YP; Chen DP; Zhuo L; Li WG
    PLoS One; 2016; 11(9):e0160437. PubMed ID: 27598699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.
    Pai SB; Pai RB; Schinazi RF
    Panminerva Med; 2003 Sep; 45(3):165-73. PubMed ID: 14618114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.